Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xihuang pill (Xihuang Wan) is a traditional Chinese medicine (TCM) formula widely utilized in China as an adjuvant therapy for various malignancies, including breast cancer, liver cancer, and cholangiocarcinoma. The formula typically consists of four primary ingredients: Calculus Bovis (Niu Huang), Moschus (She Xiang), Boswellia carterii (Ru Xiang), and Commiphora myrrha (Mo Yao). It is recognized for its anti-tumor, anti-inflammatory, and immunomodulatory properties. Mechanistically, Xihuang pill is thought to inhibit tumor cell proliferation, induce apoptosis, and modulate the immune microenvironment, potentially enhancing the efficacy of modern treatments like chemotherapy and immunotherapy while mitigating treatment-related toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xihuang pill.